How to Prepare Performance Verification Documentation for Medical Device Registration in Vietnam

Short answer: To prepare performance verification documentation for medical device registration in Vietnam, a manufacturer should first confirm the target market, the product's risk classification, the applicable regulatory pathway and the current documentation baseline, and then assess the technical file, quality management system evidence, labelling and instructions for use, local authorized representative arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a formal documentation gap assessment before submission, so that unclear classification, evidence or authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Key Takeaways

Registration in Vietnam typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality management system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of "which documents must be submitted," corrections or rework commonly arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends that companies plan this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation on a country-by-country, case-by-case basis.

This article is compiled from the AIMEILI regulatory practice question bank, the AIMEILI medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the manufacturer's own documentation baseline.

Published: 2026-07-10 18:28 · Updated: 2026-07-10 18:28

This FAQ addresses the questions companies most often need to resolve first in real international registration projects covering documentation preparation, compliance pathways and post-market maintenance.

Applicable Scenarios and Core Questions

Companies searching for guidance on preparing performance verification documentation for Vietnam registration are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a Vietnamese submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect the market launch plan. Behind this question there are usually several connected topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the procedure for a single country is not sufficient. A more valuable approach is to first produce reusable versions of the core technical file, quality management system evidence, performance verification, clinical evidence and labelling/instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, mode of body contact, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics, and then determine the risk classification and submission pathway. If the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a Vietnam project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains documentation for certificate renewal. If these points are left vague in a commercial contract only, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support each other. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and the local responsibility structure.

• Submitting directly translated domestic NMPA documentation without reorganizing the evidence according to the Vietnamese pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and claims in the registration dossier, leading to corrections or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Manufacturer Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm their documentation baseline, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, the model and specification matrix and the intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the duties, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Vietnam registration as a one-off document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to each country's requirements is usually faster, more stable, and more conducive to subsequent changes and certificate renewal than supplementing documentation on an ad hoc basis for each country.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of the local partner. If these three items are unclear, the project may still face repeated rounds of correction, agent communication and post-market maintenance issues even if the documentation appears extensive.

Frequently Follow-up Questions

Can domestic Chinese documentation be used directly for Vietnam registration?

Domestic documentation can serve as a basis, but it generally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It should be started as soon as the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, certificate renewal and post-market event handling. Unclear rights and responsibilities can affect certificate control and the stability of the subsequent market position.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and helps management judge whether the project will affect the market launch plan.

For companies that already have registration experience in several countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supported by additional statements for a specific country. In particular, the labelling and instructions for use, clinical evaluation, risk management, performance verification and quality management system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control arrangements.
• Track translation, notarization, testing and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope of the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, model and specifications or version of the instructions for use do not match the test reports, the authority may request supplementary explanations even when a large volume of documentation has been prepared.

Before submission, companies should establish an evidence consistency checklist that maps the product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and quality system certificate item by item. This step appears basic, but it can noticeably reduce the probability of corrections, and it is particularly valuable for projects submitted simultaneously in multiple GHWP member states or covering multiple product families.

Localization and Agent Responsibilities

A Vietnam registration project usually involves arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the subsequent market position.

Labels, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean the compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance; once a manufacturing address change, model expansion, instructions for use update or agent replacement occurs, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this topic within the annual international registration plan: first set target market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, correction, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country; more importantly, it allows companies to build a repeatable overseas compliance capability and reduce the cost of starting documentation preparation from scratch each time they enter a new market.

Content Review and Scope of Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgment. Scope of applicability: this article is intended for preliminary understanding, documentation preparation and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.